VCM
BIOT

Vivaldi Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Vivaldi Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$97K – 265
2021
Q3 		$97K Buy
+10,000
New +$96.9K 0.02% 330

Other funds holding BIOT

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Vivaldi Capital Management's BIOT Position: Q4 2021 in Review

Vivaldi Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q4 2021, closing a stake of 10,000 shares — an estimated $97K sold.

Vivaldi Capital Management first reported a position in BIOT in Q3 2021 and held it in 1 quarter. The position peaked at $97K in Q3 2021. 76 funds tracked by Wall St. Rank hold BIOT as of Q4 2021.

  • Vivaldi Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q4 2021 after selling out during the quarter.
  • Vivaldi Capital Management sold 10,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q4 2021, an estimated $97K.
  • Vivaldi Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2021 and held it in 1 quarter.
  • Vivaldi Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $97K in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q4 2021.

Based on Vivaldi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.